by Truveta Research | Jul 10, 2023 | Research, Research Insights
We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...
by Truveta Research | Jun 6, 2023 | Research, Research Insights
Beginning in Fall 2022, the news media has reported extensively on the use of Glucagon-like peptide-1 receptor agonist (GLP-1s) for weight loss (Belluz, 2023). Physicians have taken to TikTok to promote GLP-1s for weight loss, and celebrities & influencers – such...
by Truveta Research | May 9, 2023 | Research, Research Insights
This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes. Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease...
by Truveta Staff | May 4, 2023 | News
This post is authored by Tricia Rodriguez, senior applied scientist, Truveta Research. The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is gearing up for a fantastic event, slated for May 7-10, 2023, in Boston. As an applied scientist with...
